Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

Intracerebral haemorrhage (ICH) is a dramatic condition caused by the rupture of a cerebral
vessel and the entry of blood into the brain parenchyma. ICH is a major contributor to stroke …

Background Treatment of acute stroke, before a distinction can be made between ischemic
and hemorrhagic types, is challenging. Whether very early blood-pressure control in the …

Background Early control of elevated blood pressure is the most promising treatment for
acute intracerebral haemorrhage. We aimed to establish whether implementing a goal …

The optimal blood pressure (BP) management in acute ischaemic stroke (AIS) and acute
intracerebral haemorrhage (ICH) remains controversial. These European Stroke …

Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

Background Tranexamic acid can prevent death due to bleeding after trauma and post-
partum haemorrhage. We aimed to assess whether tranexamic acid reduces haematoma …

Introduction: Spontaneous non-traumatic intracerebral hemorrhage (ICH) is most often
caused by small vessel diseases: deep perforator arteriopathy (hypertensive arteriopathy) or …

Haematoma expansion affects a fifth of patients within 24 h of the onset of acute
intracerebral haemorrhage and is associated with death and disability, which makes it an …

Background Uncertainty persists over the effects of blood pressure lowering in acute
intracerebral haemorrhage. We aimed to combine individual patient-level data from the two …